Drug Trial Radar · NCT00662038
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,058
Actual
Start
Aug 2008
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Apr 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
pirfenidoneDrug
Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse EventsTime frame: 7.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Genentech, Inc.
South San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.